ABCL FY 2022 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$485M+29.4% YoY

Gross Profit

$419M86.3% margin

Operating Income

$217M44.6% margin

Net Income

$159M32.7% margin

EPS (Diluted)

$0.50

Cash Flow

Operating Cash Flow

$277M

Free Cash Flow

$205M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$308M

Stockholders' Equity

$1.2B

Cash & Equivalents

$387M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$485M	$375M	+29.4%
Gross Profit	$419M	$330M	+27.1%
Operating Income	$217M	$204M	+5.9%
Net Income	$159M	$153M	+3.3%